AI Article Synopsis

  • Mixed pancreatic tumors that combine epithelial and mesenchymal components are rare and often invasive.
  • A unique case of a 72-year-old woman revealed a sarcomatous change in a residual intraductal papillary mucinous neoplasm (IPMN) without any invasive features.
  • Both tumor types in the case exhibited abnormal p53 protein expression and shared a specific mutation in the KRAS gene, with no signs of relapse after 6 months.*

Article Abstract

Mixed pancreatic epithelial and mesenchymal tumors are rare, usually invasive, entities. Intraductal papillary mucinous neoplasm (IPMN) is a precursor of invasive ductal carcinoma and shares mutations with its invasive counterparts. We report the case of a 72-year-old female with a previously undescribed sarcomatous transformation of a residual IPMN with no evidence of an invasive component. The mesenchymal component showed no heterologous differentiation. Both the epithelial and the mesenchymal populations showed aberrant expression of p53 protein and the same point mutation in KRAS gene. After a 6 month follow up, there were no signs of local or distant relapse. The present case suggests that sarcomatous transformation is possible in non-invasive, intraductal pancreatic lesions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.patol.2021.05.004DOI Listing

Publication Analysis

Top Keywords

sarcomatous transformation
12
intraductal papillary
8
papillary mucinous
8
mucinous neoplasm
8
epithelial mesenchymal
8
pancreatic intraductal
4
neoplasm sarcomatous
4
transformation case
4
case report
4
report mixed
4

Similar Publications

Hemosiderotic fibrolipomatous tumor (HFLT) and myxoinflammatory fibroblastic sarcoma (MIFS) are rare, locally aggressive soft tissue tumors with a predilection for distal extremities of middle-aged adults. Hybrid tumors (HFLT-MIFS) demonstrate overlapping features of both and share recurrent translocation (1;10) (p22; q24). We describe a tumor with high-grade sarcomatous transformation of a hybrid HFLT-MIFS, with a novel gene fusion, presenting as a right foot soft tissue mass in an 85-year-old woman.

View Article and Find Full Text PDF

The mesenchymal transformations of infiltrating gliomas are uncommon events. This is particularly true of IDH-mutant astrocytomas and oligodendrogliomas, in which mesenchymal transformation is exceedingly rare. oligosarcoma is a newly recognized methylation class (MC) that represents transformed 1p/19q co-deleted oligodendrogliomas, but recent studies indicate it may be non-specific.

View Article and Find Full Text PDF

Solitary fibrous tumors (SFTs) of the central nervous system (CNS) are rare mesenchymal tumors characterized by a fusion of the NGFI-A-binding protein 2 (NAB2) gene and the signal transducer and activator of transcription 6 (STAT6) gene, immunohistochemically resulting in nuclear expression of STAT6 - an immunohistochemical hallmark essential for diagnosis, as outlined in the fifth edition of the World Health Organization Classification of Tumors. Dedifferentiation, where low-grade tumors transform into high-grade forms, has been observed in SFTs, with documented cases involving sarcomatous or rarely epithelial transformations. We report the first case of a CNS SFT exhibiting "transdedifferentiation" into epithelioid neuroendocrine differentiation.

View Article and Find Full Text PDF

Introduction: Spindle cell sarcoma (SCS) is a sarcoma subtype rarely described in the abdominal cavity, and with a worse prognosis compared with that at other sites. We report a case of SCS occurring at the anastomosis after ileal resection for colorectal cancer.

Presentation Of Case: An 86-year-old woman with a chief complaint of abdominal pain had undergone ileal resection, D2 dissection, and hand-sewn anastomosis in 2011 to treat papillary stage I adenocarcinoma.

View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma, despite treatment advancements, has a poor prognosis with less than 2 years median survival due to the unknown reasons for varied treatment responses.
  • A study analyzed glioblastoma samples from 106 patients, identifying early genetic changes like TERT promoter mutations, while later alterations varied between initial and recurrent tumors, along with diverse epigenetic changes impacting treatment outcomes.
  • Findings indicated that patients with somatic hypermutation post-treatment had better survival rates, and an epigenomic signature linked to DNA methylation changes could predict clinical results, emphasizing the complex evolution of this cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!